BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Reckitt Benckiser Plc (RB.L) Hires Key Bureaucrat Amid Suboxone Tumult


2/22/2013 7:32:25 AM

Amid a raging controversy over its strategy for promoting the Suboxone treatment for opioid dependence, Reckitt Benckiser has hired a career government bureaucrat who can help the company better navigate the curious world of opioid treatment programs and federal regulations. In a little-noticed move, Nicholas Reuter joined Reckitt earlier this month as manager of treatment health policy and government affairs, a Reckitt spokesman confirms. Reuter, who spent 37 years with the federal government, was most recently a senior public health analyst with the Substance Abuse & Mental Health Service Administration, or SAMHSA. And his crowning accomplishment was shepherding the rulemaking process for getting buprenorphine – which is sold as Suboxone and other names – into opioid treatment programs, according to Alison Knopf, editor of Alcoholism & Drug Abuse Weekly, which first reported the hiring. The rule, which took effect last month, allows opioid treatment programs to dispense the drug without various take-home restrictions. “He is a godsend to them and a huge loss to the federal government, and to anybody who wants to come up with another, cheaper alternative” to Suboxone, Knopf says. “He knows the regulations by heart, for OTPs and for… laws allowing physicians to get waivers to treat opioid addicts with an opioid. He is an encylopedia.” His arrival may not help Reckitt with all of its myriad issues surrounding Suboxone, but the timing is certainly fortuitous. Apart from combating problems with diversion and abuse, the company is working furiously to promote a newer sublingual, or film version, of its drug, while preventing generic drugmakers from selling low-cost versions of its older tablet, which is being withdrawn from the US market.

Read at Pharmalot

Pharmalot
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES